Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Carcinogenesis research has advanced from identifying driver mutations to analyzing genomic and transcriptomic data for altered pathways.
• Inactivation of BRCA1, BRCA2, or PALB2 leads to homologous recombination deficiency (HRD), a cancer phenotype.
• Targeting HRD offers therapeutic promise through synthetic lethality and modulating tumor vulnerabilities.

Purpose of the Study:

• To highlight the importance of accurate homologous recombination deficiency (HRD) detection.
• To emphasize the need for broadening patient access to novel cancer treatment options.

Main Methods:

• Genomic and transcriptomic data analysis to identify altered cancer pathways.
• Investigating mechanisms of homologous recombination deficiency (HRD) and its therapeutic implications.
• Developing and validating assays for HRD detection.

Main Results:

• Homologous recombination deficiency (HRD) is linked to specific gene inactivations (BRCA1, BRCA2, PALB2).
• Therapeutic strategies targeting HRD include PARP inhibition and exploiting synthetic lethality.
• Effective HRD detection is crucial for patient stratification and treatment selection.

Conclusions:

• Accurate HRD detection assays are essential for advancing cancer therapy.
• Expanding the patient population eligible for HRD-targeted treatments is a critical goal.
• Understanding HRD mechanisms informs the development of novel therapeutic strategies and resistance prevention.